188 related articles for article (PubMed ID: 18751689)
1. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.
Lou HY; Chang CC; Sheu MT; Chen YC; Ho HO
Eur J Clin Pharmacol; 2009 Jan; 65(1):55-64. PubMed ID: 18751689
[TBL] [Abstract][Full Text] [Related]
2. Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs).
Klotz U
Eur J Clin Pharmacol; 2009 Jan; 65(1):1-2. PubMed ID: 18958459
[No Abstract] [Full Text] [Related]
3. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
Hunfeld NG; Touw DJ; Mathot RA; van Schaik RH; Kuipers EJ
Aliment Pharmacol Ther; 2012 Apr; 35(7):810-8. PubMed ID: 22324425
[TBL] [Abstract][Full Text] [Related]
4. Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes.
Hayato S; Hasegawa S; Hojo S; Okawa H; Abe H; Sugisaki N; Munesue M; Horai Y; Ohnishi A
Eur J Clin Pharmacol; 2012 May; 68(5):579-88. PubMed ID: 22108775
[TBL] [Abstract][Full Text] [Related]
5. [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors].
Morozov SV; Tsodikova OM; Isakov VA; Gushchin AE; Shipulin GA
Eksp Klin Gastroenterol; 2003; (6):58-63, 154. PubMed ID: 15065530
[TBL] [Abstract][Full Text] [Related]
6. [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].
Sohn YH; Lee WS; Park CH; Joo YE; Kim HS; Choi SK; Rew JS; Kim SJ
Korean J Gastroenterol; 2006 Sep; 48(3):162-71. PubMed ID: 17047431
[TBL] [Abstract][Full Text] [Related]
7. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
8. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
[TBL] [Abstract][Full Text] [Related]
9. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
[TBL] [Abstract][Full Text] [Related]
10. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers.
Wang Y; Zhang H; Meng L; Wang M; Yuan H; Ou N; Zhang H; Li Z; Shi R
Eur J Clin Pharmacol; 2010 Jun; 66(6):563-9. PubMed ID: 20414645
[TBL] [Abstract][Full Text] [Related]
11. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Schwab M; Klotz U; Hofmann U; Schaeffeler E; Leodolter A; Malfertheiner P; Treiber G
Clin Pharmacol Ther; 2005 Dec; 78(6):627-34. PubMed ID: 16338278
[TBL] [Abstract][Full Text] [Related]
12. Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.
Miehlke S; Löbe S; Madisch A; Kuhlisch E; Laass M; Grossmann D; Knoth H; Morgner A; Labenz J
Aliment Pharmacol Ther; 2011 Feb; 33(4):471-6. PubMed ID: 21175704
[TBL] [Abstract][Full Text] [Related]
13. Potent Gastric Acid Inhibition Over 24 Hours by 4-Times Daily Dosing of Esomeprazole 20 mg.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Kagami T; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Digestion; 2015; 91(4):277-85. PubMed ID: 25924819
[TBL] [Abstract][Full Text] [Related]
14. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.
Kagami T; Sahara S; Ichikawa H; Uotani T; Yamade M; Sugimoto M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2016 May; 43(10):1048-59. PubMed ID: 26991399
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
Hunfeld NG; Touw DJ; Mathot RA; Mulder PG; VAN Schaik RH; Kuipers EJ; Kooiman JC; Geus WP
Aliment Pharmacol Ther; 2010 Jan; 31(1):150-9. PubMed ID: 19785625
[TBL] [Abstract][Full Text] [Related]
16. Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics.
Shimizu T; Nakayama Y; Ishii E; Ida S; Satou T; Tokuhara D; Arai K; Nii M; Rydholm H; Yajima T;
Pediatr Int; 2019 Jan; 61(1):87-95. PubMed ID: 30422368
[TBL] [Abstract][Full Text] [Related]
17. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
Sagar M; Tybring G; Dahl ML; Bertilsson L; Seensalu R
Gastroenterology; 2000 Sep; 119(3):670-6. PubMed ID: 10982760
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: a five-way crossover study.
Yang H; Li J; Zhao Q; Li J; Shen K; Yang X; Jiang J; Hu P; Qian J
J Gastroenterol Hepatol; 2013 Dec; 28(12):1823-8. PubMed ID: 23800161
[TBL] [Abstract][Full Text] [Related]
19. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
[TBL] [Abstract][Full Text] [Related]
20. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
Hu XP; Xu JM; Hu YM; Mei Q; Xu XH
J Clin Pharm Ther; 2007 Oct; 32(5):517-24. PubMed ID: 17875119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
